Two Procedures for Bleeding and Enlarged Spleen in Liver Cirrhosis Compared
Compares two procedures in adults with cirrhosis, variceal bleeding and an overactive spleen.
Plain-language title generated from the registry record
Registry title: Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism
Key facts
- Where
- Yangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cirrhosis and high pressure in the liver's blood vessels. They have had bleeding from enlarged veins in the food pipe or stomach, and an overactive spleen.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Cirrhosis with portal hypertension. Severe enlarged veins in the food pipe and stomach with acute bleeding. Bleeding came back after endoscopic variceal ligation (EVL). Hypersplenism causing a clearly low platelet and/or white blood cell count. Liver function Child-Pugh class A or B (score 7-9).
- Earlier treatment
- Must have had endoscopic variceal ligation (EVL), after which the bleeding returned.
Main reasons for not taking part
- Child-Pugh class C (score 10 or more) or MELD score above 18
- Severe right heart failure or pulmonary hypertension
- Uncontrolled infection or sepsis
- Portal vein thrombosis, portal cavernous transformation or polycystic liver disease
- Pregnancy or breastfeeding
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07490405, who can take part
Where in China
- Northern Jiangsu People's HospitalYangzhou, ChinaContact: Guoqing Jiang, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Northern Jiangsu People's Hospital
- Trial code
- NCT07490405
- Record updated
- 18 May 2026
- Original description
This study aims to compare two treatments for cirrhotic portal hypertension with acute esophagogastric variceal bleeding and hypersplenism: laparoscopic splenectomy and azygoportal disconnection (LSD) and transjugular intrahepatic portosystemic shunt (TIPS). It is a single-center, prospective trial. The primary outcome is the incidence of post-procedure hepatic encephalopathy. Secondary outcomes include changes in hepatic venous pressure gradient, portal and hepatic artery hemodynamics, liver function, renal function, complete blood count, immune function, hepatic reserve capacity, serological markers of liver fibrosis, re-bleeding rate, hepatocellular carcinoma incidence, recompensation incidence, overall survival, and bleeding-free survival. The study will provide high-level evidence for optimal treatment selection in this patient population.Read full original descriptionShow less
Long-term Efficacy and Safety of Laparoscopic Splenectomy and Azygoportal Disconnection Versus Transjugular Intrahepatic Portosystemic Shunt for Cirrhotic Portal Hypertension With Acute Esophagogastric Variceal Bleeding and Hypersplenism
This study aims to compare two treatments for cirrhotic portal hypertension with acute esophagogastric variceal bleeding and hypersplenism: laparoscopic splenectomy and azygoportal disconnection (LSD) and transjugular intrahepatic portosystemic shunt (TIPS). It is a single-center, prospective trial. The primary outcome is the incidence of post-procedure hepatic encephalopathy. Secondary outcomes include changes in hepatic venous pressure gradient, portal and hepatic artery hemodynamics, liver function, renal function, complete blood count, immune function, hepatic reserve capacity, serological markers of liver fibrosis, re-bleeding rate, hepatocellular carcinoma incidence, recompensation incidence, overall survival, and bleeding-free survival. The study will provide high-level evidence for optimal treatment selection in this patient population.
Inclusion: Confirmed diagnosis of cirrhotic portal hypertension; Endoscopic examination confirmed the presence of severe esophagogastric varices accompanied by acute bleeding. Rebleeding occurred after endoscopic variceal ligation (EVL) treatment; Presence of hypersplenism causing significant thrombocytopenia and/or leukopenia; Liver function Child-Pugh class A or B (score 7-9); Age 18-75 years; Patient provides written informed consent.
Exclusion: Severe hepatic encephalopathy (West-Haven grade III-IV) unresponsive to medication; Liver function Child-Pugh class C (score ≥10), or Model for End-Stage Liver Disease (MELD) score >18; Severe right heart failure or pulmonary hypertension; Uncontrolled systemic infection or sepsis; Polycystic liver disease, portal cavernous transformation, or portal vein thrombosis (affecting procedure or shunt creation); Advanced hepatocellular carcinoma (beyond Milan criteria) or other uncontrolled malignancies; Severe contrast agent allergy (affecting TIPS procedure); Any severe non-hepatic disease with a life expectancy <1 year; Pregnancy or lactation; Recent gastric and duodenal ulcers; Inability to comply with follow-up or provide informed consent.